Formulary Access Strategy: Why Payer Restrictions May Intensify Before Manufacturers See Them Coming
- Jul 9
- 4 min read
Updated: Jul 20
Want the downloadable brief? Get the full Signal 3 PDF and webinar replay resources from our Access Inflection resource page.
Formulary pressure is not always announced through dramatic policy changes.
More often, it shows up gradually through tighter utilization management, narrower preferred positioning, increased step edits, and greater scrutiny of products that do not clearly justify their place in the treatment pathway.
During eMAX Health Systems’ webinar, The Access Inflection: When the 2025 Playbook Stops Working, a live panel of senior payer and market access leaders discussed five signals reshaping 2026 access planning for pharmaceutical and biotech teams.
The third signal: The Quiet Formulary Crackdown.
For manufacturers, the risk is not only losing formulary position. The bigger risk is failing to see access restrictions forming until they have already changed provider behavior, patient starts, and brand performance.
Formulary Control Is Becoming More Deliberate
Payers are not only evaluating whether products should be covered. They are increasingly focused on how tightly products should be managed, when preferred status is justified, and where restrictions may be needed to control cost and utilization.
That shift matters most in crowded or high-cost categories, where multiple therapies may appear clinically similar from the payer perspective.
One panelist put it plainly:
“Best in class efficacy… that’s subjective.”
That comment is important because it highlights a disconnect manufacturers often face. A product may be positioned internally as best in class, but payers may not accept that framing unless the evidence clearly supports a meaningful difference in safety, guidelines, net cost, or overall value.
For access teams, the question is not only whether a product has a strong clinical story. It is whether that story is strong enough to influence payer coverage logic.
Differentiation Has to Be Meaningful Enough to Change Access Logic
In a tighter formulary environment, clinical differentiation needs to be more than a brand message.
Payers are looking for evidence strong enough to influence coverage, sequencing, and value assessment. As one panelist explained:
“It’s the level of evidence that is being provided to demonstrate and support that product is best in class.”
That creates a higher bar for manufacturers, especially in categories where clinical guidelines are broad, indirect comparisons are common, or multiple products are competing for similar patient populations.
A product may be clinically differentiated, but that differentiation may not automatically protect preferred positioning. If payers do not see a difference that changes the decision-making equation, access teams may face more restrictive tiering, step therapy, prior authorization, or documentation requirements.
Utilization Management Is Becoming a Stronger Access Lever
Even when a product remains covered, utilization management can reshape the real-world access experience.
Prior authorization, step edits, reauthorization criteria, and documentation requirements can all affect whether patients can start and stay on therapy. That means formulary access and practical access are not always the same thing.
One medical director described how tightly payers may connect access requirements to clinical evidence:
“We PA literally almost all biologics and all rare and orphan disease drugs to clinical trial inclusion criteria. We go tighter than the FDA label.”
For manufacturers, that is a critical planning point.
FDA approval may define the label, but payer policy may define the access pathway. If the payer’s criteria are narrower than the label, then the manufacturer’s evidence, field strategy, provider education, and pull-through planning need to account for that reality.
The Old Playbook May Miss Quiet Access Erosion
Formulary risk does not always show up as a sudden denial or exclusion.
It can build through smaller changes that make access harder over time: less favorable tiering, new documentation requirements, step-through rules, tighter reauthorization, or weaker pull-through.
That is why historical access performance may not be a reliable guide for 2026 planning. Categories are becoming more crowded, payer scrutiny is increasing, and access decisions may depend on whether manufacturers can clearly demonstrate why their product deserves preferred positioning.
As one panelist said:
“If you’re in a crowded market, or if you’re later to market, you’re going to have to demonstrate, A, how you clinically differentiate, or B, that you’re addressing an unmet need that our existing products are not addressing.”
That is the heart of the quiet formulary crackdown.
Manufacturers may not lose access all at once. They may lose momentum through small restrictions that accumulate over time.
What Manufacturers Should Pressure-Test in Their Formulary Access Strategy
For teams preparing for 2026 and 2027 planning, this signal raises several important questions:
Are we assuming formulary access will remain stable because it has been stable historically?
Have we validated how payers may narrow coverage in our category?
Is our clinical differentiation meaningful enough to protect preferred positioning?
Do we understand what utilization management requirements may emerge?
Have we tested whether providers can realistically navigate those requirements?
Does our contracting strategy reflect payer pressure to simplify and narrow formularies?
These questions matter because formulary restrictions are easier to anticipate before they are built into policy.
Once restrictions are in place, teams may be reacting to a payer strategy that could have been pressure-tested earlier.
Where MAVA® Fits
MAVA® helps pharmaceutical and biotech teams bring current payer and healthcare decision-maker insight into high-stakes access planning before market conditions shift.
For formulary planning, MAVA can help teams understand how payers may evaluate preferred positioning, utilization management, evidence requirements, contracting scenarios, and access friction before restrictions become harder to reverse.
MAVA can help teams:
Validate how payers may narrow coverage in a specific category
Understand likely prior authorization, step edit, and reauthorization requirements
Pressure-test whether clinical differentiation is meaningful enough to defend access
Explore how contracting scenarios may affect preferred positioning
Identify where provider workflow barriers may limit pull-through
Align Commercial, Medical, HEOR, Pricing, and Access teams around a more realistic formulary strategy
The goal is to help teams move from internal assumption to payer-informed strategy.
The Takeaway
Formulary pressure does not always appear as a sudden access loss. It can emerge gradually through narrower preferred positioning, tighter utilization management, and higher evidence expectations.
Manufacturers that wait for restrictions to appear in policy may already be behind. Teams that validate payer expectations earlier will be better positioned to defend access, refine evidence strategy, and anticipate where formulary friction may emerge.
The 2026 playbook needs to account for a more selective payer environment.
Now is the time to pressure-test formulary strategy before quiet restrictions become real access barriers.
